These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 16219008)

  • 1. Insulin resistance, diabetes and cardiovascular risk: approaches to treatment.
    Rosenberg DE; Jabbour SA; Goldstein BJ
    Diabetes Obes Metab; 2005 Nov; 7(6):642-53. PubMed ID: 16219008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiazolidinediones-benefits on microvascular complications of type 2 diabetes.
    Viberti G
    J Diabetes Complications; 2005; 19(3):168-77. PubMed ID: 15866064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of coronary heart disease in type 2 diabetes.
    Mykkänen L
    Int J Clin Pract Suppl; 2000 Oct; (113):40-5. PubMed ID: 11965831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus.
    Fonseca VA
    Am J Med; 2007 Sep; 120(9 Suppl 2):S18-25. PubMed ID: 17826042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosiglitazone: potential beneficial impact on cardiovascular disease.
    Viberti GC
    Int J Clin Pract; 2003 Mar; 57(2):128-34. PubMed ID: 12661797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones.
    Nesto R
    Diabet Med; 2004 Aug; 21(8):810-7. PubMed ID: 15270782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin resistance--a common link between type 2 diabetes and cardiovascular disease.
    Lebovitz HE
    Diabetes Obes Metab; 2006 May; 8(3):237-49. PubMed ID: 16634983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological treatment of diabetic patients with respect to prevention of macrovascular disease.
    Tkác T
    Acta Diabetol; 2003 Dec; 40 Suppl 2():S338-42. PubMed ID: 14704865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term benefits of insulin therapy and glycemic control in overweight and obese adults with type 2 diabetes.
    Caballero AE
    J Diabetes Complications; 2009; 23(2):143-52. PubMed ID: 18413192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
    Irons BK; Greene RS; Mazzolini TA; Edwards KL; Sleeper RB
    Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic syndrome: are we at risk?
    Paudel B
    Nepal Med Coll J; 2007 Sep; 9(3):204-11. PubMed ID: 18092442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapy of diabetes mellitus: implications for the prevention and treatment of cardiovascular disease.
    Ragucci E; Zonszein J; Frishman WH
    Heart Dis; 2003; 5(1):18-33. PubMed ID: 12549986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of oral antihyperglycemic agents in modifying macrovascular risk factors in type 2 diabetes.
    Lebovitz HE
    Diabetes Care; 1999 Apr; 22 Suppl 3():C41-4. PubMed ID: 10189561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology of cardiovascular disease in type 2 diabetes.
    Serrano Rios M
    Int J Clin Pract Suppl; 2001 Sep; (121):4-7. PubMed ID: 11594245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In support of an early polypharmacy approach to the treatment of type 2 diabetes.
    Wright EE; Stonehouse AH; Cuddihy RM
    Diabetes Obes Metab; 2010 Nov; 12(11):929-40. PubMed ID: 20880339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The metabolic syndrome, type 2 diabetes, and cardiovascular disease: understanding the role of insulin resistance.
    Kendall DM; Harmel AP
    Am J Manag Care; 2002 Dec; 8(20 Suppl):S635-53; quiz S654-7. PubMed ID: 12510788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoglycemic pharmacological treatment of type 2 diabetes: targeting the endothelium.
    Nathanson D; Nyström T
    Mol Cell Endocrinol; 2009 Jan; 297(1-2):112-26. PubMed ID: 19038307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B; Lund SS; Vaag A
    Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of diabetes in patients with severe obesity.
    Scheen AJ
    Biomed Pharmacother; 2000 Mar; 54(2):74-9. PubMed ID: 10759290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.